Cutaneous T Cell Lymphoma Ctcl Market

DelveInsight’s ‘Cutaneous T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast - 2030’ report, delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Cutaneous T-cell Lymphoma (CTCL) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The Cutaneous T-cell Lymphoma (CTCL) market report provides analysis regarding current treatment practices, emerging drugs like SGX301, Remetinostat, Pembrolizumab, AFM13, and Cobomarsen, potential therapies, market share of the individual therapies, and historical, current and forecasted CTCL market size from 2017 to 2030, segmented by seven major markets.


The report also covers current Cutaneous T-cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  •  EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • •Japan

Study Period: 2017–2030

Cutaneous T-cell Lymphoma – Disease Understanding and Treatment Algorithm

Overview:

According to National Organization for Rare Disorders (NORD), Cutaneous T-cell Lymphomas (CTCLs) are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors. Cutaneous T-cell Lymphoma is a group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Collectively, CTCL is classified as a type of non-Hodgkin lymphoma (NHL).


Cutaneous T-cell Lymphomas (CTCL) are the most common types of skin lymphoma. More than 3 out of every four skin lymphomas diagnosed are CTCLs and often appear as eczema-like skin rashes and can affect widespread parts of the body. There are different subtypes of CTCL. The recruitment of malignant T-cell clones characterizes CTCLs into the skin. Mycosis fungoides (MF) represent the most common type of CTCL and account for ~50% of all primary cutaneous lymphomas, followed by Sézary syndrome.

Treatment:

Treatment helps in reducing symptoms, risk of complications and exacerbations among persons with Cutaneous T-cell Lymphoma Patients with early-stage mycosis fungoides (MF) or sezary syndrome (SS) may respond well to skin-directed therapies alone, whereas patients with more advanced disease may require a combination of skin-directed (topical) and systemic (affecting the entire body). Patients with early-stage disease, stages I–IIA, are managed mostly with skin-directed therapies.


This chapter covers the details of conventional and current medical therapies available for the treatment of CTCL. It also provides the country-wise CTCL treatment guidelines across the United States, Europe, and Japan.


DelveInsight’s Cutaneous T-cell Lymphoma market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides CTCL treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Epidemiology:

The Cutaneous T-cell Lymphoma (CTCL) epidemiology chapters provide insights about historical and current CTCL patient pool and forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. CTCL epidemiology is segmented by the incident population of CTCL, subtype-specific incident population of CTCL, gender-specific incidence of CTCL, stage-specific incidence of CTCL (MF/SS). Besides, the report includes a thorough analysis of all segments.


According to DelveInsight’s, the total prevalent population of CTCL in seven major markets was 7,410 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).


Among all the seven major markets, total prevalent cases for Cutaneous T-cell Lymphoma were highest in the United States followed by Germany and France. Spain accounted for the least number of prevalent cases among the 7 MM.


Drug Chapters:

This segment encloses the detailed analysis of the drugs in the Cutaneous T-cell Lymphoma (CTCL) pipeline. It also helps understand the CTCL clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.


The primary purpose of treatment is to improve a patient’s quality of life. Several factors determine a patient’s treatment plan, including the person’s general health, age and the stage of the disease. The effective therapies which are used during the advanced stage (stage IIB-IV) of CTCL are HDAC inhibitors, i.e., Istodax (romidepsin) and Zolinza (vorinostat).

Market Outlook:

The market size of Cutaneous T-cell Lymphoma (CTCL) is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounted for the largest CTCL market size. Among EU5 countries, Germany had the largest market size, with USD 40.59 million in 2017, while Spain had the smallest market size of CTCL, with USD 17.91 million in 2017.

Drugs Uptake:

This section focuses on the rate of uptake of the potential drugs in the Cutaneous T-cell Lymphoma (CTCL) market or expected to get launched in the market during the study period 2017–2030. The analysis covers CTCL market uptake by drugs; patient uptake by therapies; and sale of each drug.


It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Pembrolizumab (Merck Sharp & Dohme Corp.), AFM13 (Affimed GmbH.), BNZ-1 (Bioniz Therapeutics), Tislelizumab (BeiGene) and Cobomarsen (miRagen Therapeutics, Inc.) are some of the major players that are going to alter the market dynamics in the coming years.during the forecasted period 2020-2030.

Cutaneous T-cell Lymphoma : Pipeline Development Activities

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.

Pipeline Development Activities:

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning radiation-induced esophagitis.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Cutaneous T-cell Lymphoma domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We have performed the competitive and market Intelligence analysis of the Cutaneous T-cell Lymphoma Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.

Report Highlights:

  • In the coming years, Cutaneous T-cell Lymphoma market scenario is not expected to experience a positive shift across the 7MM due to approved treatment options and a robust pipeline.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Cutaneous T-cell Lymphoma Report Insights:

  • Patient Population
  • Therapeutic Approaches
  • Cutaneous T-cell Lymphoma Pipeline Analysis
  • Cutaneous T-cell Lymphoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Cutaneous T-cell Lymphoma Report Key Strengths:

  • 11-years Forecast
  • 7MM Coverage
  • Cutaneous T-cell Lymphoma Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Cutaneous T-cell Lymphoma Report Assessment:

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Cutaneous T-cell Lymphoma (CTCL) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Cutaneous T-cell Lymphoma (CTCL) total market size as well as market size by therapies across the 7MM during the forecast period (2017–2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Cutaneous T-cell Lymphoma market size during the forecast period (2017–2030)?
  • At what CAGR, the Cutaneous T-cell Lymphoma (CTCL) market is expected to grow in 7MM during the forecast period (2017–2030)?
  • What would be the Cutaneous T-cell Lymphoma market (CTCL) outlook across the 7MM during the forecast period (2017–2030)?
  • What would be the Cutaneous T-cell Lymphoma (CTCL) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden and unmet needs of Cutaneous T-cell Lymphoma (CTCL)?
  • What is the historical Cutaneous T-cell Lymphoma (CTCL) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Cutaneous T-cell Lymphoma (CTCL) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Cutaneous T-cell Lymphoma (CTCL)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Cutaneous T-cell Lymphoma (CTCL) during the forecast period (2017–2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Cutaneous T-cell Lymphoma (CTCL) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Cutaneous T-cell Lymphoma (CTCL) in the USA, Europe, and Japan?
  • What are the Cutaneous T-cell Lymphoma (CTCL) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Cutaneous T-cell Lymphoma (CTCL)?
  • How many therapies are developed by each company for Cutaneous T-cell Lymphoma (CTCL)?
  • How many are emerging therapies in mid-stage, and Late-stage of development for Cutaneous T-cell Lymphoma (CTCL) treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cutaneous T-cell Lymphoma (CTCL) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cutaneous T-cell Lymphoma (CTCL) and their status?
  • What are the key designations that have been granted for the emerging therapies for Cutaneous T-cell Lymphoma (CTCL)?
  • What is the global historical and forecasted market of Cutaneous T-cell Lymphoma (CTCL)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Cutaneous T-cell Lymphoma (CTCL) market
  • To understand the future market competition in the Cutaneous T-cell Lymphoma (CTCL) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-cell Lymphoma (CTCL) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-cell Lymphoma (CTCL) market
  • To understand the future market competition in the Cutaneous T-cell Lymphoma (CTCL) market

Which geography accounted for the largest Cutaneous T-cell Lymphoma market size?

The United States accounted for the largest CTCL market size.


What is forecasted Cutaneous T-cell Lymphoma size in 2030?

DelveInsight estimates an increase in CTCL Market Size during the study period, 2017–2030


What are the present Cutaneous T-cell Lymphoma drivers?

Rising healthcare expenditure, Emerging therapies, Genetic advancements leading to better disease understanding


What are the Cutaneous T-cell Lymphoma market barriers?

Adverse side effects of the therapies, High Cost of Treatment, Lack of awareness


How many companies are developing drugs for Cutaneous T-cell Lymphoma?

Currently, more than six key pharma players are developing the drug for CTCL.


Which are the leading companies in Cutaneous T-cell Lymphoma market?

Key Players – Merck Sharp & Dohme Corp., Affimed GmbH., Bioniz Therapeutics, BeiGene and miRagen Therapeutics, Inc.


How is epidemiology segmented for Cutaneous T-cell Lymphoma?

Incident population of CTCL, Subtype-specific incident population of CTCL, Gender-specific incidence of CTCL, Stage-specific incidence of CTCL (MF/SS)

1 Key Insights

2 Executive Summary of Cutaneous T-cell Lymphoma

3 SWOT Analysis for Cutaneous T-cell Lymphoma

4 Cutaneous T-cell Lymphoma Epidemiology Overview at a Glance

4.1 Patient Share (%) Distribution of Cutaneous T-cell Lymphoma in 2017

4.2 Patient Share (%) Distribution of Cutaneous T-cell Lymphoma in 2030

5 Cutaneous T-cell Lymphoma Market Overview at a Glance

5.1 Market Share (%) Distribution of Cutaneous T-cell Lymphoma in 2017

5.2 Market Share (%) Distribution of Cutaneous T-cell Lymphoma in 2030

6 Disease Background and Overview

6.1 Introduction

6.2 Classification

6.3 Staging

6.4 Symptoms

6.5 Etiopathogenesis

6.6 The genomic landscape of SS/MF

6.7 Biomarkers

6.8 Diagnosis

6.9 Staging and Assessment

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Total Incident Population of CTCL in 7MM

8 Country Wise-Epidemiology of Cutaneous T-cell Lymphoma

8.1 The United States

8.1.1 Incident Population of CTCL in the United States

8.1.2 Subtype-specific Incident Population of CTCL in the United States

8.1.3 Gender-specific Incidence of CTCL in the United States

8.1.4 Stage-specific Incidence of CTCL (MF/SS) in the United States

8.1.4.1 Early-stage-specific Incidence of CTCL in the United States

8.1.4.2 Late-stage-specific Incidence of CTCL in the United States

8.2 EU5

8.2.1 Germany

8.2.1.1 Incident Population of CTCL in Germany

8.2.1.2 Subtype-specific Incident Population of CTCL in Germany

8.2.1.3 Gender-specific Incidence of CTCL in Germany

8.2.1.4 Stage-specific Incidence of CTCL (MF/SS) in Germany

8.2.1.4.1 Early-stage-specific Incidence of CTCL in Germany

8.2.1.4.2 Late-stage-specific Incidence of CTCL in Germany

8.2.2 France

8.2.2.1 Incident Population of CTCL in the France

8.2.2.2 Subtype-specific Incident Population of CTCL in France

8.2.2.3 Gender-specific Incidence of CTCL in France

8.2.2.4 Stage-specific Incidence of CTCL (MF/SS) in France

8.2.2.4.1 Early-stage-specific Incidence of CTCL in the France

8.2.2.4.2 Late-stage-specific Incidence of CTCL in France

8.2.3 Italy

8.2.3.1 Incident Population of CTCL in Italy

8.2.3.2 Subtype-specific Incident Population of CTCL in Italy

8.2.3.3 Gender-specific Incidence of CTCL in the Italy

8.2.3.4 Stage-specific Incidence of CTCL (MF/SS) in the Italy

8.2.3.4.1 Early-stage-specific Incidence of CTCL in Italy

8.2.3.4.2 Late-stage-specific Incidence of CTCL in Italy

8.2.4 Spain

8.2.4.1 Incident Population of CTCL in Spain

8.2.4.2 Subtype-specific Incident Population of CTCL in the Spain

8.2.4.3 Gender-specific Incidence of CTCL in the Spain

8.2.4.4 Stage-specific Incidence of CTCL (MF/SS) in Spain

8.2.4.4.1 Early-stage-specific Incidence of CTCL in Spain

8.2.4.4.2 Late-stage-specific Incidence of CTCL in Spain

8.2.5 The United Kingdom

8.2.5.1 Incident Population of CTCL in the United Kingdom

8.2.5.2 Subtype-specific Incident Population of CTCL in the United Kingdom

8.2.5.3 Gender-specific Incidence of CTCL in the United Kingdom

8.2.5.4 Stage-specific Incidence of CTCL (MF/SS) in the United Kingdom

8.2.5.4.1 Early-stage-specific Incidence of CTCL in the United Kingdom

8.2.5.4.2 Late-stage-specific Incidence of CTCL in the United Kingdom

8.3 Japan

8.3.1.1 Incident Population of CTCL in Japan

8.3.1.2 Subtype-specific Incident Population of CTCL in the Japan

8.3.1.3 Gender-specific Incidence of CTCL in Japan

8.3.1.4 Stage-specific Incidence of CTCL (MF/SS) in the Japan

8.3.1.4.1 Early-stage-specific Incidence of CTCL in Japan

8.3.1.4.2 Late-stage-specific Incidence of CTCL in Japan

9 Treatment and Management

9.1 International Lymphoma Radiation Oncology Group Guidelines

9.2 United States

9.2.1 NCCN Guidelines

9.3 Europe

9.3.1 ESMO Guidelines

9.3.2 Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines

9.3.3 EORTC recommendations for the treatment of mycosis fungoides/Se´zary syndrome

9.3.4 Japanese Guidelines

9.4 Patient Journey

10 Unmet Needs

11 Case Study

12 Marketed Therapies

12.1 Istodax (Romidepsin): Celgene Corporation

12.1.1 Product Description

12.1.2 Product Development Activity

12.1.3 Advantages and Disadvantages

12.1.4 Safety and Efficacy

12.2 Potelegio (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.

12.2.1 Product Description

12.2.2 Product Development activity

12.2.3 Advantages & Disadvantages

12.2.4 Safety and Efficacy

12.3 Valchlor/ Ledaga (Mechlorethamine): Actelion

12.3.1 Product Description

12.3.2 Product Development Activity

12.3.3 Advantages & Disadvantages

12.3.4 Safety and Efficacy

12.4 Uvadex (Methoxsalen): Mallinckrodt Pharmaceuticals

12.4.1 Product Description

12.4.2 Product Development Activity

12.4.3 Advantages and Disadvantages

12.4.4 Safety and Efficacy

12.5 Targretin (Bexarotene): Eisai Co., Ltd.

12.5.1 Product Description

12.5.2 Product Development Activities

12.5.3 Advantages and Disadvantages

12.5.4 Safety and Efficacy of Targretin

12.6 Zolinza (Vorinostat): Merck Sharp & Dohme Corp.

12.6.1 Product Description

12.6.2 Advantages & Disadvantages

12.6.3 Safety and Efficacy of Zolinza

12.7 Adcetris (Brentuximab Vedotin): Seattle Genetics

12.7.1 Product Description

12.7.2 Product Development Activity

12.7.3 Advantages and Disadvantages

12.7.4 Safety and Efficacy of Adcetris

13 Emerging Therapies

13.1 SGX301: Soligenix

13.1.1 Product Description

13.1.2 Regulatory Milestones

13.1.3 Clinical Development

13.1.3.1 Clinical Trials Description

13.1.4 Safety and Efficacy

13.2 Resminostat: 4SC AG

13.2.1 Product Description

13.2.2 Regulatory Milestones

13.2.3 Clinical Development

13.2.3.1 Clinical Trials Information

13.3 Remetinostat: Medivir AB

13.3.1 Product Description

13.3.2 Regulatory Milestones

13.3.3 Clinical Development

13.3.3.1 Clinical Trials Information

13.3.4 Safety and Efficacy

13.4 Pembrolizumab: Merck

13.4.1 Product Description

13.4.2 Clinical Development

13.4.2.1 Clinical Trials Information

13.5 AFM13: Affimed

13.5.1 Product Description

13.5.2 Product Development Activities

13.5.3 Clinical Development

13.5.3.1 Clinical Trials Information

13.5.4 Safety and Efficacy

13.6 Cobomarsen: miRagen Therapeutics

13.6.1 Product Description

13.6.2 Clinical Development

13.6.2.1 Clinical Trials Information

13.6.3 Safety and Efficacy

13.7 E7777: Eisai, Inc.

13.7.1 Product Description

13.7.2 Other Developmental Activities

13.7.3 Regulatory Milestones

13.7.4 Clinical Development

13.7.4.1 Clinical Trials Information

13.7.5 Safety and Efficacy

14 Other Promising Candidates

14.1 BNZ-1: Bioniz Therapeutics

14.1.1 Product Description

14.1.2 Product Development Activities

14.1.3 Clinical Development

14.1.3.1 Clinical Trials Information

14.1.4 Safety and Efficacy

14.2 CD11301: Galderma R&D

14.2.1 Product Description

14.2.2 Clinical Development

14.2.2.1 Clinical Trials Information

14.3 Lacutamab/IPH4102: Innate Pharma

14.3.1 Product Description

14.3.2 Other Developmental Activities

14.4 Tislelizumab: BeiGene

14.4.1 Product Description

14.4.2 Clinical Development

14.4.2.1 Clinical Trials Information

14.5 Resimmune: Angimmune

14.5.1 Product Description

14.5.2 Other Developmental Activities

15 Dormant Products

15.1 Quisinostat: Janssen

15.1.1 Product Description

15.1.2 Regulatory Milestones

15.1.3 Clinical Development

15.1.3.1 Clinical Trials Information

15.1.4 Safety and Efficacy

16 Cutaneous T-cell Lymphoma: Seven Major Market Analysis

16.1 Key Findings

16.2 Market Size of Cutaneous T-cell Lymphoma (CTCL) in 7MM

16.3 Drug Analysis at a Glance

17 Market Outlook by Country

17.1 United States

17.1.1 Market Outlook

17.1.2 Total Market Size of Cutaneous T-cell Lymphoma (CTCL) in the US

17.1.3 Early-stage Market Size of CTCL by First Line of Therapies in the US

17.1.4 Early-stage Market Size of CTCL by Second Line of Therapies in the US

17.1.5 Late-stage Market Size of CTCL by First Line of Therapies in the US

17.1.6 Late-stage Market Size of CTCL by Second Line of Therapies in the US

17.2 EU-5 Countries: Market Outlook

17.2.1 Germany

17.2.1.1 Total Market Size of Cutaneous T-cell Lymphoma (CTCL) in Germany

17.2.1.2 Early-stage Market Size of CTCL by First Line of Therapies in Germany

17.2.1.3 Early-stage Market Size of CTCL by Second Line of Therapies in Gemany

17.2.1.4 Late-stage Market Size of CTCL by First Line of Therapies in the US

17.2.1.5 Late-stage Market Size of CTCL by Second Line of Therapies in the US

17.2.2 France

17.2.2.1 Total Market Size of Cutaneous T-cell Lymphoma (CTCL) in France

17.2.2.2 Early-stage Market Size of CTCL by First Line of Therapies in France

17.2.2.3 Early-stage Market Size of CTCL by Second Line of Therapies in France

17.2.2.4 Late-stage Market Size of CTCL by First Line of Therapies in France

17.2.2.5 Late-stage Market Size of CTCL by Second Line of Therapies in France

17.2.3 Italy

17.2.3.1 Total Market Size of Cutaneous T-cell Lymphoma (CTCL) in Italy

17.2.3.2 Early-stage Market Size of CTCL by First Line of Therapies in Italy

17.2.3.3 Early-stage Market Size of CTCL by Second Line of Therapies in the US

17.2.3.4 Late-stage Market Size of CTCL by First Line of Therapies in the US

17.2.3.5 Late-stage Market Size of CTCL by Second Line of Therapies in Italy

17.2.4 Spain

17.2.4.1 Total Market Size of Cutaneous T-cell Lymphoma (CTCL) in Spain

17.2.4.2 Early-stage Market Size of CTCL by First Line of Therapies in Spain

17.2.4.3 Early-stage Market Size of CTCL by Second Line of Therapies in Spain

17.2.4.4 Late-stage Market Size of CTCL by First Line of Therapies in Spain

17.2.4.5 Late-stage Market Size of CTCL by Second Line of Therapies in Spain

17.2.5 UK

17.2.5.1 Total Market Size of Cutaneous T-cell Lymphoma (CTCL) in the UK

17.2.5.2 Early-stage Market Size of CTCL by First Line of Therapies in the US

17.2.5.3 Early-stage Market Size of CTCL by Second Line of Therapies in the UK

17.2.5.4 Late-stage Market Size of CTCL by First Line of Therapies in the UK

17.2.5.5 Late-stage Market Size of CTCL by Second Line of Therapies in the UK

17.3 Market Outlook: Japan

17.3.1 Total Market Size of Cutaneous T-cell Lymphoma (CTCL) Japan

17.3.2 Early-stage Market Size of CTCL by First Line of Therapies in Japan

17.3.3 Early-stage Market Size of CTCL by Second Line of Therapies I Japan

17.3.4 Late-stage Market Size of CTCL by First Line of Therapies in Japan

17.3.5 Late-stage Market Size of CTCL by Second Line of Therapies in Japan

18 Market Drivers

19 Market Barriers

20 Appendix

20.1 Report Methodology

21 DelveInsight Capabilities

22 Disclaimer

23 About DelveInsight

List of Tables

Table 1: Summary of Cutaneous T- Cell Lymphoma (CTCL) Market, Epidemiology, and Key Events (2017–2030)

Table 2: TNMB Classification and Staging of Mycosis Fungoides and Sezary Syndrome

Table 3: Clinical Staging of Mycosis Fungoides and Sezary Syndrome

Table 4: Total Incident Population of CTCL in 7MM(2017-2030)

Table 5: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017–2030)

Table 6: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017–2030)

Table 7: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017–2030)

Table 8: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017–2030)

Table 9: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017–2030)

Table 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017–2030)

Table 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017–2030)

Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017–2030)

Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017–2030)

Table 14: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017–2030)

Table 15: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017–2030)

Table 16: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017–2030)

Table 17: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017–2030)

Table 18: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017–2030)

Table 19: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017–2030)

Table 20: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017–2030)

Table 21: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017–2030)

Table 22: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017–2030)

Table 23: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017–2030)

Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017–2030)

Table 25: Incident Population of Cutaneous T-Cell Lymphoma in the UK (2017–2030)

Table 26: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the UK (2017–2030)

Table 27: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the UK (2017–2030)

Table 28: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in the UK (2017–2030)

Table 29: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017–2030)

Table 30: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017–2030)

Table 31: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017–2030)

Table 32: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017–2030)

Table 33 : Recommendations for treatment of CTCL by Radiation Therapy

Table 34: BAD Guidelines for Mycosis Fungoides and Sezary Syndrome

Table 35 : Recommendations for treatment of MF stages IA, IB, and IIA

Table 36: Soligenix, Clinical Trial Description, 2020

Table 37: Pembrolizumab, Clinical Trial Description, 2019

Table 38: Remetinostat, Clinical Trial Description, 2020

Table 39: Pembrolizumab, Clinical Trial Description, 2020

Table 40: AFM13, Clinical Trial Description, 2020

Table 41: Cobomarsen, Clinical Trial Description, 2020

Table 42: E7777, Clinical Trial Description, 2020

Table 43: BNZ-1, Clinical Trial Description, 2020

Table 44: CD11301, Clinical Trial Description, 2020

Table 45 : Tislelizumab, Clinical Trial Description, 2020

Table 46: 7 Major Market Size of CTCL in USD Million (2017–2030)

Table 47: United States Market Size of Cutaneous T- Cell Lymphoma (CTCL) in USD Million (2017–2030)

Table 48: Early Stage Market size of CTCL by First line of therapies in the US, in USD Million (2017–2030)

Table 49: Early Stage Market size of CTCL by First line of therapies in the US, in USD Million (2017–2030)

Table 50: Late Stage Market size of CTCL by First line of therapies in the US, in USD Million (2017–2030)

Table 51: Late Stage Market size of CTCL by Second line of therapies in the US, in USD Million (2017–2030)

Table 52: Germany Market Size of Cutaneous T- Cell Lymphoma (CTCL) in USD Million (2017–2030)

Table 53: Early Stage Market size of CTCL by First line of therapies in Germany, in USD Million (2017–2030)

Table 54: Early Stage Market size of CTCL by Second line of therapies in Germany, in USD Million (2017–2030)

Table 55: Late Stage Market size of CTCL by First line of therapies in Germany, in USD Million (2017–2030)

Table 56: Late Stage Market size of CTCL by Second line of therapies in Germany, in USD Million (2017–2030)

Table 57: France Market Size of Cutaneous T- Cell Lymphoma (CTCL) in USD Million (2017–2030)

Table 58: Early Stage Market size of CTCL by First line of therapies in France, in USD Million (2017–2030)

Table 59: Early Stage Market size of CTCL by Second line of therapies in France, in USD Million (2017–2030)

Table 60: Late Stage Market size of CTCL by First line of therapies in France , in USD Million (2017–2030)

Table 61: Late Stage Market size of CTCL by Second line of therapies in France, in USD Million (2017–2030)

Table 62: Italy Market Size of Cutaneous T- Cell Lymphoma (CTCL) in USD Million (2017–2030)

Table 63: Early Stage Market size of CTCL by First line of therapies in Italy, in USD Million (2017–2030)

Table 64: Early Stage Market size of CTCL by Second line of therapies in Italy, in USD Million (2017–2030)

Table 65: Late Stage Market size of CTCL by First line of therapies in Italy, in USD Million (2017–2030)

Table 66: Late Stage Market size of CTCL by Second line of therapies in Italy, in USD Million (2017–2030)

Table 67: Spain Market Size of Cutaneous T- Cell Lymphoma (CTCL) in USD Million (2017–2030)

Table 68: Early Stage Market size of CTCL by First line of therapies in Spain, in USD Million (2017–2030)

Table 69: Early Stage Market size of CTCL by Second line of therapies in Spaiin, in USD Million (2017–2030)

Table 70: Late Stage Market size of CTCL by First line of therapies in Spain , in USD Million (2017–2030)

Table 71: Late Stage Market size of CTCL by Second line of therapies in Spain, in USD Million (2017–2030)

Table 72: UK Market Size of Cutaneous T- Cell Lymphoma (CTCL) in USD Million (2017-2030)

Table 73: Early Stage Market size of CTCL by First line of therapies in the UK, in USD Million (2017–2030)

Table 74: Early Stage Market size of CTCL by Second line of therapies in the UK, in USD Million (2017–2030)

Table 75: Late Stage Market size of CTCL by First line of therapies in the UK, in USD Million (2017–2030)

Table 76: Late Stage Market size of CTCL by Second line of therapies in the UK, in USD Million (2017–2030)

Table 77: Japan Market Size of Cutaneous T- Cell Lymphoma (CTCL) in USD Million (2017-2030)

Table 79: Early Stage Market size of CTCL by Second line of therapies in Japan, in USD Million (2017–2030)

Table 80: Late Stage Market size of CTCL by First line of therapies in Japan, in USD Million (2017-2030)

Table 81: Late Stage Market size of CTCL by Second line of therapies in Japan, in USD Million (2017-2030)

List of Figures

Figure 1: SWOT Analysis

Figure 2: Staging of Cutaneous T-Cell Lymphoma: TNMB Classification

Figure 3: Total Incident Population of CTCL in 7MM (2017-2030)

Figure 4: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017–2030)

Figure 5: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017–2030)

Figure 6: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017–2030)

Figure 7: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017–2030)

Figure 8: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017–2030)

Figure 9: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017–2030)

Figure 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017–2030)

Figure 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017–2030)

Figure 12: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017–2030)

Figure 13: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017–2030)

Figure 14: Incident Population of Cutaneous T-Cell Lymphoma in France (2017–2030)

Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017–2030)

Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017–2030)

Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017–2030)

Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017–2030)

Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017–2030)

Figure 20: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017–2030)

Figure 21: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017–2030)

Figure 22: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017–2030)

Figure 23: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017–2030)

Figure 24: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017–2030)

Figure 25: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017–2030)

Figure 26: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017–2030)

Figure 27: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017–2030)

Figure 28: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017–2030)

Figure 29: Incident Population of Cutaneous T-Cell Lymphoma in the UK (2017–2030)

Figure 30: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the UK (2017–2030)

Figure 31: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the UK (2017–2030)

Figure 32: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in the UK (2017–2030)

Figure 33: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in the UK (2017–2030)

Figure 34: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017–2030)

Figure 35: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017–2030)

Figure 36: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017–2030)

Figure 37: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan(2017–2030)

Figure 38: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017–2030)

Figure 39: Treatment Algorithm of Cutaneous T- Cell Lymphoma

Figure 40: Treatment Algorithm of Cutaneous T- Cell Lymphoma

Figure 41: Treatment for Stage IA of Cutaneous T- Cell Lymphoma

Figure 42: Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma

Figure 43: Treatment for Stage IIB of Cutaneous T- Cell Lymphoma

Figure 44: Treatment for Stage III of Cutaneous T- Cell Lymphoma

Figure 45: Treatment for Stage IV of Cutaneous T- Cell Lymphoma

Figure 46: Suggested treatment regimen for Cutaneous T- Cell Lymphoma

Figure 47: Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders

Figure 48: Unmet Needs of Cutaneous T- Cell Lymphoma (CTCL)

Figure 50: 7 Major Market Size of Cutaneous T- Cell Lymphoma in USD Million (2017–2030)

Figure 51: Market Size of Cutaneous T- Cell Lymphoma (CTCL) in the United States, USD Millions (2017–2030)

Figure 52: Early Stage Market size of CTCL by First line of therapies in the US, in USD Million (2017–2030)

Figure 53: Early Stage Market size of CTCL by Second line of therapies in the US, in USD Million (2017–2030)

Figure 54: Late Stage Market size of CTCL by First line of therapies in the US, in USD Million (2017–2030)

Figure 55: Late Stage Market size of CTCL by Second line of therapies in the US, in USD Million (2017–2030)

Figure 56: Market Size of Cutaneous T- Cell Lymphoma (CTCL) in Germany, USD Millions (2017–2030)

Figure 57: Early Stage Market size of CTCL by First line of therapies in Germany, in USD Million (2017–2030)

Figure 58: Early Stage Market size of CTCL by Second line of therapies in Germany, in USD Million (2017–2030)

Figure 59: Late Stage Market size of CTCL by First line of therapies in the US, in USD Million (2017–2030)

Figure 60: Late Stage Market size of CTCL by Second line of therapies in Germany, in USD Million (2017–2030)

Figure 61: Market Size of Cutaneous T- Cell Lymphoma (CTCL) in France, USD Millions (2017–2030)

Figure 62: Early Stage Market size of CTCL by First line of therapies in France, in USD Million (2017–2030)

Figure 63: Early Stage Market size of CTCL by Second line of therapies in France, in USD Million (2017–2030)

Figure 64: Late Stage Market size of CTCL by First line of therapies in France, in USD Million (2017–2030)

Figure 65: Late Stage Market size of CTCL by Second line of therapies in France, in USD Million (2017–2030)

Figure 66: Market Size of Cutaneous T- Cell Lymphoma (CTCL) in Italy, USD Millions (2017–2030)

Figure 67: Early Stage Market size of CTCL by First line of therapies in Italy, in USD Million (2017–2030)

Figure 68: Early Stage Market size of CTCL by Second line of therapies in Italy, in USD Million (2017–2030)

Figure 69: Late Stage Market size of CTCL by First line of therapies in Italy, in USD Million (2017–2030)

Figure 70: Late Stage Market size of CTCL by Second line of therapies in Italy, in USD Million (2017–2030)

Figure 71: Market Size of Cutaneous T- Cell Lymphoma (CTCL) in the Spain, USD Millions (2017–2030)

Figure 72: Early Stage Market size of CTCL by First line of therapies in Spain, in USD Million (2017–2030)

Figure 73: Early Stage Market size of CTCL by Second line of therapies in Spain, in USD Million (2017–2030)

Figure 74: Late Stage Market size of CTCL by First line of therapies in Spain, in USD Million (2017–2030)

Figure 75: Late Stage Market size of CTCL by Second line of therapies in Spain, in USD Million (2017–2030)

Figure 76: Market Size of Cutaneous T- Cell Lymphoma (CTCL) in the UK, USD Millions (2017–2030)

Figure 77: Early Stage Market size of CTCL by First line of therapies in the US, in USD Million (2017–2030)

Figure 78: Early Stage Market size of CTCL by Second line of therapies in the UK, in USD Million (2017–2030)

Figure 79: Late Stage Market size of CTCL by First line of therapies in the UK, in USD Million (2017–2030)

Figure 80: Late Stage Market size of CTCL by Second line of therapies in the UK, in USD Million (2017–2030)

Figure 81: Market Size of Cutaneous T- Cell Lymphoma (CTCL) in Japan, USD Millions (2017–2030)

Figure 82: Early Stage Market size of CTCL by First line of therapies in Japan, in USD Million (2017-2030)

Figure 83: Early Stage Market size of CTCL by Second line of therapies in Japan, in USD Million (2017–2030)

Figure 84: Late Stage Market size of CTCL by First line of therapies in Japan, in USD Million (2017-2030)

Figure 85: Late Stage Market size of CTCL by Second line of therapies in Japan, in USD Million (2017-2030)

Figure 86:Market Drivers

Figure 87:Market Barriers for CTCL

• Merck Sharp & Dohme Corp

• Affimed GmbH

• Bioniz Therapeutics

• BeiGene

• miRagen Therapeutics, Inc

  • Tags:
  • Cutaneous T-Cell Lymphoma(CTCL) mar...
  • Cutaneous T-Cell Lymphoma(CTCL) mar...
  • Cutaneous T-Cell Lymphoma(CTCL) mar...
  • Cutaneous T-Cell Lymphoma(CTCL) mar...
  • Cutaneous T-Cell Lymphoma(CTCL) mar...
  • Cutaneous

Forward to Friend

Need A Quote